Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.7 |
mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.7 |
mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | -0.0098 | 0.7 |